852520-41-3

Basic information

• Product Name: Methyl 3-isopropoxy-5-(2-(3-thienyl)ethoxy)benzoate
• Synonyms: Methyl 3-isopropoxy-5-(2-(3-thienyl)ethoxy)benzoate
• CAS NO: 852520-41-3
• Molecular Weight: 320.409
• Mol File: 852520-41-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Methyl 3-isopropoxy-5-(2-(3-thienyl)ethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-isopropoxy-5-(2-(3-thienyl)ethoxy)benzoate(852520-41-3)
• EPA Substance Registry System: Methyl 3-isopropoxy-5-(2-(3-thienyl)ethoxy)benzoate(852520-41-3)

Safety Data

• Hazardous Substances Data: 852520-41-3(Hazardous Substances Data)

Upstream product

• 13781-67-4 3-(2-hydroxyethyl)thiophene 
• 752242-26-5 methyl 3-hydroxy-5-isopropoxybenzoate 
• 57070-76-5 2-(3'-thiophenyl)-1-bromoethane 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 

Downstream Products

• 852520-62-8 methyl 6-(3-isopropoxy-5-(2-(3-thienyl)ethoxy)benzamido)nicotinate 
• 852520-52-6 3-Isopropoxy-5-(2-(3-thienyl)ethoxy)benzoic acid 

Relevant articles and documents

Small-molecule allosteric activation of human glucokinase in the absence of glucose

Synthetic allosteric activators of human glucokinase are receiving considerable attention as potential diabetes therapeutic agents. Although their mechanism of action is not fully understood, structural studies suggest that activator association requires

NOVEL ACTIVATORS OF GLUCOKINASE

The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistence and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.